TECVAYLI®▼ (teclistamab) Patient Card

Carry this card with you at all times.
SHOW THIS CARD to any healthcare professional involved in your care and if you go to the hospital

FOLD HERE

Teclistamab can cause side effects such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).[1] CRS and ICANS are serious immune reactions that may require immediate medical attention.

PATIENT'S NAME:

_____

FOLD HERE

Important Safety Information for Patients

Get medical help straight away if you experience any of the following:[1]

Cytokine Release Syndrome (CRS)

- Fever (38°C or higher)
- Chills
- Fast heartbeat
- Difficulty breathing
- Nausea
- Headache
- Feeling dizzy

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

- Feeling confused
- Feeling less alert
- Having difficulty writing
- Having difficulty speaking
- Sleepiness
- Loss of ability to carry out skilled movement and gestures (despite having the physical ability and desire to perform them)

FOLD HERE

IMPORTANT TO REMEMBER: Stay close to the location of the healthcare facility where you received your teclistamab therapy for at least 2 days for daily monitoring after administration of your first three doses (usually two step-up doses and first treatment dose).[1]

If you have **any** of the symptoms listed on this card call your doctor or nurse, or seek emergency medical attention right away. These are not all the possible side effects of this medicine. Tell your doctor or nurse if you have any side effect that bothers you or does not go away.

Prescribing Doctor

PRESCRIBING DOCTOR'S NAME:

PRESCRIBING DOCTOR'S PHONE NUMBER:

HOSPITAL NAME AND ADDRESS:

PHONE NUMBER:

FOLD HERE

Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of teclistamab injections (step-up dosing schedule):

STEP-UP DOSE 1

STEP-UP DOSE 2

FIRST TREATMENT DOSE*

*This is the first full treatment dose (1.5 mg/kg)[1]

FOLD HERE

Important Safety Information for Healthcare Professionals

This patient is receiving teclistamab. CRS and ICANS may occur in patients receiving teclistamab, and can be fatal or life-threatening.

Assess the patient for signs and symptoms of CRS and ICANS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's prescribing doctor immediately for further information.

See Summary of Product Characteristics for full details.[1]

FOLD HERE

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects via: HPRA Pharmacovigilance, Website: www.hpra.ie. Adverse events should also be reported to Janssen Sciences Ireland UC, a Johnson and Johnson company, on +44 1494 567 447 or email dsafety@its.jnj.com.

1. Summary of Product Characteristics – TECVAYLI (teclistamab)
EM-209783 | Date of approval: October 2026